Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors

R. Bagatell(Memorial Sloan Kettering Cancer Center), Lia Gore(Children's Hospital Colorado), Frank M. Balis(National Institutes of Health), Tanya Trippett(Memorial Sloan Kettering Cancer Center), Elizabeth Fox(Children's National), Alberta Aikin(Memorial Sloan Kettering Cancer Center), Georgina Cirrincione‐Dall(Memorial Sloan Kettering Cancer Center), J. Bish(Memorial Sloan Kettering Cancer Center), Patricia Whitcomb(Memorial Sloan Kettering Cancer Center), Margaret E. Macy(Children's Hospital Colorado), Sergey Yurasov(Memorial Sloan Kettering Cancer Center), Cynthia E. Herzog(Memorial Sloan Kettering Cancer Center), Joseph F. Grippo(Inflarx (Germany)), Gail S. Wright(Memorial Sloan Kettering Cancer Center)
Clinical Cancer Research
December 2, 2010
10.1158/1078-0432.ccr-10-1731
Cited by 48

Related Papers

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia
|JAMA|2021|358
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|341
Mobilization of hobo elements residing within the decapentaplegic gene complex: Suggestion of a new hybrid dysgenesis system in Drosophila melanogaster
|Cell|1987|190